updat model reflect acquisit
yet adjust model pend dental ipo concurr increas
price target maintain outperform rate
updat model reflect acquisit model
assum includ result begin januari
increas revenu forecast includ full year contribut
ge biopharma arriv base assumpt acquir revenu grow
y/i revenu base manag indic
expect recal expect revenu growth approxim
updat model assum revenu grow annual
model period think bia like upsid especi
better integrates/cross-sel bioprocess portfolio out-year
estim accret overal core
revenu growth accret core revenu growth life scienc
increas gross margin estim reflect accret synergi
associ stand-alone gross margin vs
core expect major cost save deriv cog
save forecast annual gross margin expans beyond
notabl get compani year synergi target see table/
analysi herein sale synergi think ge could grow target/forecast
 annual gross margin synergi vs base oper synergi vs
base point forecast line manag guidanc believ
ampl sourc upsid
increas oper margin estim reflect accret
synergi associ stand-alone oper margin
low-to-mid vs core
conserv forecast tax rate remain stabl
opportun optim tax rate
increas interest expens estim account ge
biopharma relat debt interest notabl expect achiev
leverag ratio end
continu page
pleas see page report import disclosur
remain enthus long-term outlook particularli subsequ ge
biopharma deal appear well-posit gener sustain revenu
growth ep growth expect continu deploy capit tuck-in
acquisit near-term expect compani posit complet larger
ep upsid year
ep upsid year
capit deploy drive ep
diversifi multi-industri compani signific presenc health care
environment test manufactur market becom focus
health care compani spin-off juli sale gener
life scienc diagnost dental market danah histor success larg
function strong manag team danah busi system db
estim prefer dividend approxim annual subtract
net incom common sharehold estim
increas dilut common share outstand estim account
common stock offer associ deal
increas ep estim manag year
accret guidanc expect exceed ep accret target
see clear path ep accret year guidanc assum year
increas price target base dcf analysi new
price target impli pro forma price-to-earnings repres premium peer
group believ ultim beat ep estim
acknowledg stock great run thu far
like exhaust primari upsid driver meaning
capac least next year addit share trade slight premium
peer pro forma basi accordingli dont think much stock upsid
near-term continu view core long-term tool hold
compani report thomson eikon cowen compani
transact assumptionsaccretion/dilutionassum close bioadjustments-matot purchas price purchas price net tax synergiesgm synergiesgm synergiesm consideration/equitygross share deal y/ysynergiesgrowth y/ysynergiessynergiesoper rate new debt net exist net exist gross gross gross sg sg sg debt/ebitdainterest expens ttm end biopharma new new debt debt debt biopharma biopharma biopharma valuationtot transact transact ebitda tax tax tax tax transact prefer prefer prefer transact ebitda valuat outstand outstand outstand outstand cowen
compani report thomson eikon cowen compani
mm except yr core revenu growth fxreport growth currenc core growth fx reiter organ fewer sell day extra exchang core growth jan growth comment note averag core revenu growthconst currenc point higher average last yearsorgan total foreign exchang core growth jan growth currenc total like contribut growth legaci dxforeign exchang core growth jan flat/lsdreport growth currenc total exchang appli core growth jan growth currenc total exchang comment cepheid flu revenu like repres core growth headwind headwind almost point cowen comment year stack basi comparison tougher next quarter compar last cowen
compani report thomson eikon cowen compani
mm except yr cagrcommentsnet core revenu growth fxreport core growth fx reiter organ fewer sell day extra gener cost synergi total oper increment margin pull core core oper margin expansionincrement oper margin excl fx jun pall cost synergi non-oper interest interest rate swap earn tax rateadjust prefer net incom ep jan share consensu except gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
downsid risk includ limit macroeconom deterior
current level inabl execut integr eros market share price
due competit inabl deliv margin target value-destruct
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock danah corpor secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc april et dissemin april et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
